Scholarly Index
Olivier Rascol
Inserm; 52,227 total citations; 621 total publications; best world rank #4
Inserm
52,227Total citations
621Total publications
109H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 19 | FR 2 | 99.85 |
| Botulinum Toxin and Related Neurological Disorders | Lifetime | 19 | FR 1 | 99.80 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 30 | FR 2 | 99.85 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 4 | FR 1 | 99.43 |
| Genetic Neurodegenerative Diseases | Lifetime | 193 | FR 11 | 98.81 |
| Autism Spectrum Disorder Research | Lifetime | 263 | FR 5 | 98.51 |
| Restless Legs Syndrome Research | Lifetime | 56 | FR 3 | 98.11 |
| Transcranial Magnetic Stimulation Studies | Lifetime | 436 | FR 20 | 96.60 |
| Nuclear Receptors and Signaling | Lifetime | 331 | FR 15 | 95.43 |
| Ginkgo biloba and Cashew Applications | Lifetime | 760 | FR 25 | 78.72 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 42 | FR 2 | 99.17 |
| Neuromodulation and Treatments for Neurological Disorders | 2021-2025 | 36 | FR 1 | 99.01 |
| Botulinum Toxin and Related Neurological Disorders | 2021-2025 | 45 | FR 2 | 97.48 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 452 | FR 21 | 87.70 |
| Nuclear Receptors and Signaling | 2021-2025 | 194 | FR 5 | 77.20 |